Furthermore, we confirm that the CDK4/6 inhibitor SHR6390 significantly sensitized pyrotinib in the pyrotinib‐refractory AVATAR model, which was similar to the result in the study of HER2‐positive BC.20 This evidence concerns the gene ERBB2 and breast cancer.